"Double-hit" mature B-cell lymphomas show a common immunophenotype by flow cytometry that includes decreased CD20 expression

American Journal of Clinical Pathology

Volumn 134, Issue 2, 2010, Pages 258-265

  Wu, David ^a   Wood, Brent L ^a   Dorer, Russell ^b   Fromm, Jonathan R ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

BCL2; BCL6; c MYC; CD20; Double hit; Dual translocation; Flow cytometry

Indexed keywords

CD20 ANTIGEN; MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL 6;

ADULT; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; COHORT ANALYSIS; CYTOGENETICS; DATA BASE; DOUBLE HIT MATURE B CELL LYMPHOMA; FEMALE; FLOW CYTOMETRY; GENE TRANSLOCATION; HUMAN; IMMUNOPHENOTYPING; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIGENS, CD20; CELL SEPARATION; FLOW CYTOMETRY; GENES, BCL-2; GENES, MYC; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, B-CELL; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-6; RETROSPECTIVE STUDIES; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 77955593631     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP7YLDTJPLCE5F     Document Type: Article

References (19)

1. Kanungo A, Medeiros LJ, Abruzzo LV, et al. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol. 2006;19:25-33. (Pubitemid 43250976)
2. Lin P, Medeiros LJ. High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis. Haematologica. 2007;92:1297-1301. (Pubitemid 350144145)
3. Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010;34:327-340.
4. Hasserjian RP, Ott G, Elenitoba-Johnson KS, et al. Commentary on the WHO classification of tumors of lymphoid tissues (2008): "gray zone" lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma [published online ahead of print June 27, 2009]. J Hematop. doi:10.1007/s12308- 009-0039-7.
5. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114:2273-2279.
6. Le Gouill S, Talmant P, Touzeau C, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica. 2007;92:1335-1342. (Pubitemid 350144150)
7. Niitsu N, Okamoto M, Miura I, et al. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia. 2009;23:777-783.
8. Tomita N, Tokunaka M, Nakamura N, et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica. 2009;94:935-943.
9. Rodig SJ, Vergilio JA, Shahsafaei A, et al. Characteristic expression patterns of TCL1, CD38, and CD44 identify aggressive lymphomas harboring a MYC translocation. Am J Surg Pathol. 2008;32:113-122.
10. Maleki A, Seegmiller AC, Uddin N, et al. Bright CD38 expression is an indicator of MYC rearrangement. Leuk Lymphoma. 2009;50:1054-1057.
11. Wood B. 9-color and 10-color flow cytometry in the clinical laboratory. Arch Pathol Lab Med. 2006;130:680-690. (Pubitemid 43736872)
12. Wood BL. Ten-color immunophenotyping of hematopoietic cells. Curr Protoc Cytom. 2005;Chapter 6:Unit 6.21.
13. Mantei K, Wood BL. Flow cytometric evaluation of CD38 expression assists in distinguishing follicular hyperplasia from follicular lymphoma. Cytometry B Clin Cytom. 2009;76:315-320.
14. Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood. 2008;111:3941-3967.
15. Hiraga J, Tomita A, Sugimoto T, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood. 2009;113:4885-4893.
16. Johnson NA, Boyle M, Bashashati A, et al. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood. 2009;113:3773-3780.
17. Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res. 2008;14:1561-1570. (Pubitemid 351413941)
18. Zhao XF, Hassan A, Perry A, et al. c-MYC rearrangements are frequent in aggressive mature B-cell lymphoma with atypical morphology. Int J Clin Exp Pathol. 2008;1:65-74.
19. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008;111:5486-5495.